Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Trevi Therapeutics Inc (NASDAQ: TRVI) closed at $9.99 down -8.68% from its previous closing price of $10.94. In other words, the price has decreased by -$8.68 from its previous closing price. On the day, 1.28 million shares were traded. TRVI stock price reached its highest trading level at $11.0874 during the session, while it also had its lowest trading level at $9.97.
Ratios:
For a deeper understanding of Trevi Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.93 and its Current Ratio is at 21.93. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on November 13, 2025, initiated with a Outperform rating and assigned the stock a target price of $13.
On August 21, 2025, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $18.
On July 01, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.Cantor Fitzgerald initiated its Overweight rating on July 01, 2025, with a $25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 07 ’25 when Delfini Lisa bought 108,650 shares for $9.50 per share.
Delfini Lisa bought 40,000 shares of TRVI for $386,716 on Oct 03 ’25. On Aug 27 ’25, another insider, Delfini Lisa, who serves as the Officer of the company, bought 312,855 shares for $8.09 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 1281019008 and an Enterprise Value of 1086915072.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.95, which has changed by 1.5163727 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $14.39, while it has fallen to a 52-week low of $3.73. The 50-Day Moving Average of the stock is -16.97%, while the 200-Day Moving Average is calculated to be 14.82%.
Shares Statistics:
For the past three months, TRVI has traded an average of 1.79M shares per day and 1322930 over the past ten days. A total of 128.22M shares are outstanding, with a floating share count of 83.78M. Insiders hold about 34.67% of the company’s shares, while institutions hold 69.54% stake in the company. Shares short for TRVI as of 1767139200 were 14105563 with a Short Ratio of 7.89, compared to 1764288000 on 13403743. Therefore, it implies a Short% of Shares Outstanding of 14105563 and a Short% of Float of 12.65.
Earnings Estimates
A comprehensive evaluation of Trevi Therapeutics Inc (TRVI) is underway, with the input of 8.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.09 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.35 and -$0.4 for the fiscal current year, implying an average EPS of -$0.37. EPS for the following year is -$0.47, with 8.0 analysts recommending between -$0.22 and -$0.66.
